Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Data ReadoutNeutral

AI Analysis

Summary

Sanofi and Regeneron announced plans to broaden their partnership while Bristol Myers delayed two study readouts. Apnimed, backed by Shionogi, went public as part of a continued trend of upsized biotech IPOs.

Outcome Details

Bristol Myers delayed two anticipated study readouts

Importance:5/10

Sentiment:

0.10

PartnershipIPOClinical DelayRegeneronSanofiBristol Myers

Related Companies

$SNY $REGN $BMY $SGIOY

Read the original article

Published by BioPharma Dive on July 31, 2026 3:06 PM

Read Original